WHO ICTRP trial
The efficacy of SGLT2 inhibitor for aging.
JPRN-jRCTs031250234 · Japan Primary Registries Network (JPRN) · Recruiting
Key facts
| Trial ID | JPRN-jRCTs031250234 |
|---|---|
| Public title | The efficacy of SGLT2 inhibitor for aging. |
| Scientific title | Randomized trial to test the efficacy of SGLT2 inhibitor for biological aging. |
| Primary sponsor | Minamino Tohru |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 4 |
| Conditions | Biologiccal aging Biologiccal aging |
| Interventions | After obtaining consent and allocation, the study drug group will take one 10 mg tablet of the study drug once a day after breakfast. If the attending physician deems it necessary, the following changes may be made only when used for the… |
| Registration date | Jul 16, 2025 |
| Target size | 50 |
| Registry page | jrct.mhlw.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: